Ecto-NTPDase-Inhibitors – Inhibitors for use in human therapy
The invention provides a new class of nucleosides
exhibiting a high affinity for individual ecto-nucleotidetriphosphate- diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors). Therapeutic compounds which facilitate the signal transduction via P2-receptors can be used e.g. for the treatment of mucoviscidosis and cancer or for the modulation of inflammatory processes and the immune system. Furthermore, such compounds are valuable tools in biopharmaceutical research. The present invention thus comprises a novel class of therapeutically active compounds as well as methods for preparing the same.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A universal framework for spatial biology
SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…
How complex biological processes arise
A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…